Supernus Debt Financing Update with U.S. Bank Trust Company, National Association
Supernus, Inc. announced an adjustment to the conversion rate for its 0.625% Convertible Senior Notes due 2031 following a previously declared special dividend. The conversion rate increased from 24.0033 to 30.9355 shares per $1,000 principal amount, resulting in a new conversion price of approximately $32.33 per share.
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior Pharmaceuticals completed its previously announced merger with Supernus Pharmaceuticals, with the combined entity renamed Supernus, Inc. (Nasdaq: SUPN). To fund a $1.0 billion special cash dividend to legacy Indivior stockholders, the company entered into a $650 million senior secured term loan facility with Citibank.
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior reported record Q3 2026 financial results while providing a status update on its pending all-stock merger of equals with Supernus Pharmaceuticals. The merger, which has received shareholder approval, is expected to close on November 2, 2026, with the combined company operating as Supernus, Inc. (ticker: SUPN).
Counterparty
Supernus Pharmaceuticals, Inc.
“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda. Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda.”
Joe Ciaffoni, Chief Executive Officer
“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2100 basis points year-over-year.”
Stockholders of Indivior Pharmaceuticals, Inc. approved the issuance of common stock in connection with a previously announced merger agreement. The vote satisfies Nasdaq Rule 5635 requirements for the share issuance, marking a key step toward completing the acquisition.
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. provided a status update on its pending merger with Supernus Pharmaceuticals, Inc., specifically addressing supplemental disclosures to the joint proxy statement/prospectus. The update follows demand letters and complaints from Supernus stockholders alleging disclosure deficiencies, which the company believes are meritless but is addressing to avoid litigation risk. The special meetings for stockholders of both companies to vote on the merger are scheduled for October 15, 2026.
Indivior Pharmaceuticals declared a special cash dividend of $8.13 per share to be paid to stockholders of record as of October 30, 2026. The payment is strictly contingent upon the closing of Indivior's pending merger with Supernus Pharmaceuticals, which is expected to occur on or about November 2, 2026. Supernus stockholders will not receive this dividend for shares received as merger consideration.
Indivior Pharmaceuticals Deal Termination with Reckitt Benckiser Healthcare Limited
Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited entered into a Deed of Variation and Termination to accelerate the end of their Copacker Supply Agreement for SUBOXONE and SUBUTEX tablets to January 15, 2027. Indivior has identified a new supplier and will pay RB fixed or capped costs related to the early termination, including asset disposal and redundancy costs. The company stated the financial impact of the termination and the new supplier agreement is not expected to be material.